Loading
A phase 1/2 trial of Risvutatug Rezetecan in advanced solid tumours, run by GlaxoSmithKline, now recruiting.
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) is a phase 1/2 interventional study registered as NCT06885034 by GlaxoSmithKline, with 451 participants planned, started 2025-06-11 and due to reach its primary completion in 2028-01-10. Interventions recorded: Risvutatug Rezetecan, Drug 1, Drug 2, Drug 3 and Drug 4.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/